<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361944</url>
  </required_header>
  <id_info>
    <org_study_id>131128</org_study_id>
    <secondary_id>R01GM112871</secondary_id>
    <nct_id>NCT02361944</nct_id>
  </id_info>
  <brief_title>Risk of Oxygen During Cardiac Surgery Trial</brief_title>
  <acronym>ROCS</acronym>
  <official_title>Risk of Oxygen During Cardiac Surgery (ROCS) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will recruit and randomize 200 elective cardiac surgery patients to receive&#xD;
      physiologic oxygenation (normoxia) or hyper-oxygenation (hyperoxia) during surgery to test&#xD;
      the hypothesis that intraoperative physiologic oxygenation decreases the generation of&#xD;
      reactive oxygen species, oxidative damage, and postoperative organ injury compared to&#xD;
      hyper-oxygenation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 5, 2016</start_date>
  <completion_date type="Anticipated">October 3, 2021</completion_date>
  <primary_completion_date type="Actual">October 3, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxidative damage is the primary outcome of aim 2 (mechanism of organ injury)</measure>
    <time_frame>up to 2 days following surgery</time_frame>
    <description>quantified by measuring F2-isoprostanes/isofurans</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acute kidney injury is the primary outcome of aim 1 (organ injury)</measure>
    <time_frame>up to 1 week following surgery</time_frame>
    <description>quantified by change in serum creatinine concentration (primary endpoint), KDIGO criteria, and urine concentrations of IGFBP7, TIMP-2, and NGAL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vascular reactivity / endothelial function</measure>
    <time_frame>up to 2 days following surgery</time_frame>
    <description>measured by brachial artery flow mediated dilation, peripheral artery tonometry, tension wire myogrpahy from arterioles dissected from epicardial fat, and biomarkers including PAI-1 and e-selectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mitochondrial function</measure>
    <time_frame>up to 2 days following surgery</time_frame>
    <description>in peripheral blood mononuclear cells and atrial myocardium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arrythmia</measure>
    <time_frame>duration of hospitalization, average of 6 days following surgery</time_frame>
    <description>atrial fibriallation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial injury or infarction</measure>
    <time_frame>duration of hospitalization, average of 6 days following surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>duration of hospitalization, average of 6 days following surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative cognitive dysfunction, pain, and depression</measure>
    <time_frame>up to 18 months following surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>up to 18 months following surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory failure</measure>
    <time_frame>duration of hospitalization, average of 6 days following surgery</time_frame>
    <description>PF ratios, reintubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic kidney disease</measure>
    <time_frame>up to 18 months following surgery</time_frame>
    <description>MAKE criteria (eGFR, dialysis, death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>up to 2 days following surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemolysis</measure>
    <time_frame>up to 2 days following surgery</time_frame>
    <description>plasma free hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reactive oxygen species production</measure>
    <time_frame>up to 1 day following surgery</time_frame>
    <description>TMH and CAT1H electron spin probes, and dihydroethidium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute brain dysfunction (delirium)</measure>
    <time_frame>up to 1 week following surgery</time_frame>
    <description>assessed by CAM-ICU twice daily while patients are in the ICU or for first 3 postoperative days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygenation and perfusion</measure>
    <time_frame>up to 1 day following surgery</time_frame>
    <description>hemoglobin O2 saturation, PaO2, brain and muscle oxygenation using NIRS, mixed venous O2 saturation, cardiac output, arterial lactate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Normoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperoxia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen (normoxia vs. hyperoxia)</intervention_name>
    <arm_group_label>Hyperoxia</arm_group_label>
    <arm_group_label>Normoxia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Open-heart cardiac surgery, defined as surgery on the heart or aorta that requires&#xD;
             sternotomy or thoracotomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current acute coronary syndrome (defined as ST elevation myocardial infarction or&#xD;
             non-ST elevation myocardial infarction (troponin leak within 72 hours of surgery or&#xD;
             consent +/- EKG changes consistent with myocardial ischemia)).&#xD;
&#xD;
          -  Home supplemental oxygen use.&#xD;
&#xD;
          -  Preoperative supplemental oxygen requirement to maintain arterial O2 sat of 92%.&#xD;
&#xD;
          -  Right to left intracardiac shunt including atrial septal defect and ventricular septal&#xD;
             defect with Cor Pulmonale.&#xD;
&#xD;
          -  Carotid stenosis defined as &gt;50% stenosis.&#xD;
&#xD;
          -  Cardiac surgery that requires intraoperative circulatory arrest, such as aortic arch&#xD;
             replacement.&#xD;
&#xD;
          -  Current use of hemo- or peritoneal dialysis.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic T. Billings, IV, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2015</study_first_posted>
  <disposition_first_submitted>April 4, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>April 4, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 6, 2021</disposition_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Frederic T Billings IV</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>oxygen</keyword>
  <keyword>hyperoxia</keyword>
  <keyword>reactive oxygen species</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>oxidative damage</keyword>
  <keyword>endothelial function</keyword>
  <keyword>vascular reactivity</keyword>
  <keyword>mitochondrial function</keyword>
  <keyword>surgery</keyword>
  <keyword>anesthesia</keyword>
  <keyword>kidney injury</keyword>
  <keyword>renal failure</keyword>
  <keyword>delirium</keyword>
  <keyword>myocardial injury</keyword>
  <keyword>arrythmia</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

